A major drugmaker will pay more than $2 billion in what's being called one of the largest healthcare fraud settlements in U.S. history.
The U.S. Justice Department department says Johnson and Johnson AND its subsidiaries marketed three drugs for conditions they weren't approved to treat, and paid kickbacks to doctors and pharmacists, to promote their use.
The drugs are the antipsychotics---Risperdal and Invega----and the heart medication Natrecor.
The settlement says Johnson and Johnson promoted Risperdal, to treat anxiety and agitation in elderly dementia patients, knowing it increased the risk of stroke and diabetes.
The company's subsidiary, Janssen, also agreed to pay civil penalties for promoting Natrecor, the heart drug in patients it wasn't approved to treat.
To see more on the settlement, go to www.justice.gov/opa/jj-pc-docs.html.